Caribou Biosciences, Inc.

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cell therapies. The company leverages its proprietary CRISPR-Cas9 genome-editing technology to develop innovative allogeneic cell therapies designed to treat serious diseases, with an initial focus on hematologic malignancies and autoimmune disorders. Caribou's platform allows for the creation of "off-the-shelf" cell therapies, meaning they can be manufactured in advance and readily administered to patients, potentially overcoming the manufacturing complexities and patient-specific challenges associated with autologous cell therapies. The company's lead product candidate, CB-010, is an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, as well as various forms of systemic lupus erythematosus. Further advancing its pipeline, Caribou is developing CB-011, an anti-BCMA allogeneic CAR-T cell therapy in Phase 1 trials for relapsed or refractory multiple myeloma, and CB-012, an allogeneic anti-CD371 CAR-T cell therapy also in Phase 1 trials for relapsed or refractory acute myeloid leukemia. By focusing on allogeneic approaches, Caribou aims to establish a significant competitive advantage in the rapidly evolving cell therapy landscape, offering a potentially more accessible and scalable treatment option for a broad patient population.